Annuncio pubblicitario
Italia markets closed
  • FTSE MIB

    34.249,77
    +310,02 (+0,91%)
     
  • Dow Jones

    38.307,77
    +221,97 (+0,58%)
     
  • Nasdaq

    15.960,83
    +349,07 (+2,24%)
     
  • Nikkei 225

    37.934,76
    +306,28 (+0,81%)
     
  • Petrolio

    83,85
    +0,28 (+0,34%)
     
  • Bitcoin EUR

    59.530,08
    -829,28 (-1,37%)
     
  • CMC Crypto 200

    1.324,28
    -72,25 (-5,17%)
     
  • Oro

    2.346,90
    +4,40 (+0,19%)
     
  • EUR/USD

    1,0700
    -0,0033 (-0,31%)
     
  • S&P 500

    5.110,62
    +62,20 (+1,23%)
     
  • HANG SENG

    17.651,15
    +366,61 (+2,12%)
     
  • Euro Stoxx 50

    5.006,85
    +67,84 (+1,37%)
     
  • EUR/GBP

    0,8564
    -0,0010 (-0,12%)
     
  • EUR/CHF

    0,9774
    -0,0011 (-0,11%)
     
  • EUR/CAD

    1,4624
    -0,0025 (-0,17%)
     

Gritstone bio to Present at 41st Annual J.P. Morgan Healthcare Conference

Gritstone bio
Gritstone bio

EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference occurring January 9-12, 2023 in San Francisco. The presentation will take place on Thursday, January 12, 2023 from 9:45 - 10:25 AM Pacific Time in Elizabethan A conference room.

A webcast of the presentation will be available at https://ir.gritstonebio.com/investors/events. An archived replay will be accessible for 30 days following the event.

About Gritstone bio
Gritstone is working to create the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets and have programs in viral diseases and solid tumors. Independently and with our partners, we are advancing a portfolio of product candidates with the aim of improving patient outcomes and eliminating disease. www.gritstonebio.com

ANNUNCIO PUBBLICITARIO

Gritstone Contacts
Investors:
George E. MacDougall
Director, Investor Relations & Corporate Communications
Gritstone bio, Inc.
ir@gritstone.com

Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com